Polymyalgia Rheumatica: Rituximab Study

We are investigating whether rituximab can help reduce the need for corticosteroids in people with relapsing polymyalgia rheumatica. This study compares rituximab to a placebo to assess its effectiveness.

1-2 years 6-10 visits Monitoring phase (IV)Cost Reimbursement Partially Remote Standard Medicines InjectionGastroenterologyRheumatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Rituximab

Rituximab is a substance that targets and reduces B cells, a type of white blood cell, to treat some blood cancers and autoimmune conditions.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Meander Medisch Centrum Stichting

Rheumatology

Amersfoort, Netherlands

Gelre Hospitals

Rheumatology

Apeldoorn, Netherlands

Rijnstate Ziekenhuis Stichting

Rheumatology

Arnhem, Netherlands

Sponsor: Sint Maartenskliniek Stichting

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.